UY33958A - Inhibidores de la glucosilceramida sintasa - Google Patents

Inhibidores de la glucosilceramida sintasa

Info

Publication number
UY33958A
UY33958A UY33958A UY33958A UY33958A UY 33958 A UY33958 A UY 33958A UY 33958 A UY33958 A UY 33958A UY 33958 A UY33958 A UY 33958A UY 33958 A UY33958 A UY 33958A
Authority
UY
Uruguay
Prior art keywords
glucosilceramide
sintasa
inhibitors
página
escanear
Prior art date
Application number
UY33958A
Other languages
English (en)
Inventor
Bourque Elyse
Celatka Cassandra
Hirth Bradford
Metz Marcus
Zhao Zhong
Skerlj Renato
Xiang Yibin
Jancisics Katherine
Marshall John
Cheng Seng
Scheule Ronald
Mario Cabrera-Salazar
Good Andrew
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of UY33958A publication Critical patent/UY33958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Abstract

La invención se relaciona con los inhibidores de la glucosilceramida sintasa (GCS) que sirve para el tratamiento de enfermedades metabólicas, como enfermedades de almacenamiento lisosómico, ya sea solo o en combinación con terapia de reemplazo de enzimas, y para el tratamiento del cáncer.
UY33958A 2011-03-18 2012-03-16 Inhibidores de la glucosilceramida sintasa UY33958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454034P 2011-03-18 2011-03-18
US201261590711P 2012-01-25 2012-01-25

Publications (1)

Publication Number Publication Date
UY33958A true UY33958A (es) 2012-10-31

Family

ID=46879977

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33958A UY33958A (es) 2011-03-18 2012-03-16 Inhibidores de la glucosilceramida sintasa

Country Status (36)

Country Link
US (5) US9139580B2 (es)
EP (2) EP2685986B1 (es)
JP (2) JP6117708B2 (es)
KR (1) KR101987736B1 (es)
CN (2) CN107080747B (es)
AR (1) AR085425A1 (es)
AU (2) AU2012231275A1 (es)
BR (2) BR112013023774B1 (es)
CA (1) CA2830540C (es)
CL (1) CL2013002688A1 (es)
CO (1) CO6801749A2 (es)
CR (1) CR20190034A (es)
DK (1) DK2685986T3 (es)
DO (1) DOP2013000209A (es)
EC (1) ECSP13012978A (es)
ES (1) ES2774293T3 (es)
GT (1) GT201300215A (es)
HR (1) HRP20200226T1 (es)
HU (1) HUE047888T2 (es)
IL (1) IL228514B (es)
LT (1) LT2685986T (es)
MA (1) MA35023B1 (es)
MX (3) MX368340B (es)
MY (1) MY173998A (es)
NI (1) NI201300083A (es)
PE (1) PE20140412A1 (es)
PL (1) PL2685986T3 (es)
PT (1) PT2685986T (es)
RS (1) RS59963B1 (es)
RU (2) RU2018104472A (es)
SI (1) SI2685986T1 (es)
TW (2) TWI634119B (es)
UA (1) UA118248C2 (es)
UY (1) UY33958A (es)
WO (1) WO2012129084A2 (es)
ZA (1) ZA201307016B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2685986T (pt) * 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
AU2019222801B2 (en) * 2012-09-11 2021-02-18 Genzyme Corporation Glucosylceramide synthase inhibitors
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
AU2014235132B2 (en) * 2013-03-15 2018-08-02 Genzyme Corporation Method of preparing glucosylceramide synthase inhibitors
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
SG10201804952QA (en) * 2013-12-11 2018-07-30 Genzyme Corp Glucosylceramide synthase inhibitors
CN106659697B (zh) * 2014-05-30 2022-03-29 斯菲叶尔制药私有公司 作为抗结核剂的化合物
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
CN108290894A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途
EP3317265A4 (en) * 2015-07-01 2019-04-17 Northwestern University SUBSTITUTED CHINAZOLIN COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CA3018745A1 (en) 2016-03-25 2017-09-28 Genzyme Corporation Biomarkers of proteopathies and uses thereof
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
CA3043709A1 (en) 2016-11-14 2018-05-17 Berg Llc Methods for treating parkinson's disease
PT3562821T (pt) 2016-12-28 2021-03-03 Minoryx Therapeutics S L Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade
EP3562811B1 (en) 2016-12-29 2022-03-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
CN108341822B (zh) * 2017-01-23 2021-04-16 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和应用
US11498904B2 (en) * 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EP3728265A1 (en) 2017-12-21 2020-10-28 BIAL - BioTech Investments, Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
WO2019151269A1 (ja) * 2018-01-31 2019-08-08 武田薬品工業株式会社 複素環化合物
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
KR102342902B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102342901B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102233530B1 (ko) * 2018-11-22 2021-03-31 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
BR112021015099A2 (pt) 2019-02-04 2021-10-05 Genzyme Corporation Métodos para tratar sintomas e distúrbios associados a doenças de armazenamento lisossômico
JP2022519131A (ja) 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
EP4005638A4 (en) * 2019-07-29 2023-07-05 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
JP2022553107A (ja) 2019-10-23 2022-12-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
WO2021096239A1 (en) * 2019-11-15 2021-05-20 Yuhan Corporation Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
MX2022005679A (es) * 2019-11-15 2022-06-27 Yuhan Corp Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden.
CN115397806A (zh) 2019-11-25 2022-11-25 增益治疗股份有限公司 芳基和杂芳基化合物及其在与半乳糖脑苷脂酶的活性改变相关的病状中的治疗用途
WO2021105908A1 (en) 2019-11-25 2021-06-03 Gain Therapeutics Sa Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
AU2021215396A1 (en) * 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
CA3164707A1 (en) 2020-02-03 2021-08-12 Ana Maria Garcia Collazo Combination therapy for treating mps1
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
US20230212123A1 (en) 2020-04-28 2023-07-06 The Regents Of The University Of Michigan Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
CA3216293A1 (en) * 2021-05-11 2022-11-17 Dong-Hoon Kim Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the sam
WO2023042177A1 (en) 2021-09-20 2023-03-23 Gt Gain Therapeutics Sa Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
WO2023239892A1 (en) * 2022-06-10 2023-12-14 Arkuda Therapeutics Compounds for modulation of cd68 and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1988002477A1 (en) * 1986-10-03 1988-04-07 Micro Motion, Inc. Density insensitive coriolis mass flow rate meter
AU611976B2 (en) 1987-12-24 1991-06-27 John Wyeth & Brother Limited Aroyl urea and carbamic acid derivatives of azabicyclo compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
KR970701174A (ko) * 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
KR19990067403A (ko) * 1995-11-08 1999-08-16 이곤 이 버그 1-아자바이시클로헵탄 유도체 및 이의 약제학적용도
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
CA2441896A1 (en) * 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
DE60216830T2 (de) * 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
JP2003267977A (ja) * 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
AU2003248122A1 (en) 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
ES2293086T3 (es) * 2002-12-06 2008-03-16 The Feinstein Institute For Medical Research Inhibicion de la inflamacion usando agonistas colinergicos de union al receptor alfa 7.
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
JP2008504282A (ja) * 2004-06-23 2008-02-14 ザ ファインスタイン インスティテュート フォー メディカル リサーチ コリンレセプターの薬理活性により腸閉塞を処置する方法
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
EP1976519A2 (en) * 2006-01-27 2008-10-08 Yale University Cytisine and acetylcholine analogs and methods of treating mood disorders
US7840109B2 (en) * 2006-08-14 2010-11-23 Adc Telecommunications, Inc. Factory spliced cable assembly
WO2009073564A1 (en) * 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
US8389517B2 (en) * 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US20110237538A1 (en) * 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
US20100242354A1 (en) 2009-06-09 2010-09-30 Sundrop Fuels, Inc. Systems and methods for reactor chemistry and control
EP3482767B1 (en) 2009-08-28 2021-10-06 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PT2685986T (pt) * 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase

Also Published As

Publication number Publication date
JP6420860B2 (ja) 2018-11-07
MY173998A (en) 2020-03-03
ECSP13012978A (es) 2015-04-30
US20210261557A1 (en) 2021-08-26
CN107080747A (zh) 2017-08-22
PT2685986T (pt) 2020-03-05
MA35023B1 (fr) 2014-04-03
TW201716404A (zh) 2017-05-16
EP3673906A1 (en) 2020-07-01
US20200048266A1 (en) 2020-02-13
MX365245B (es) 2019-05-28
CA2830540A1 (en) 2012-09-27
US9139580B2 (en) 2015-09-22
RU2013146550A (ru) 2015-04-27
KR20140092239A (ko) 2014-07-23
IL228514A0 (en) 2013-12-31
CA2830540C (en) 2021-04-27
EP2685986B1 (en) 2019-11-27
AR085425A1 (es) 2013-10-02
DK2685986T3 (da) 2020-03-02
DOP2013000209A (es) 2014-04-15
PE20140412A1 (es) 2014-04-01
BR122019017719B1 (pt) 2022-08-23
TWI634119B (zh) 2018-09-01
WO2012129084A3 (en) 2014-04-24
BR112013023774A2 (pt) 2016-12-06
NZ615857A (en) 2016-08-26
ES2774293T3 (es) 2020-07-20
CR20190034A (es) 2019-05-20
BR112013023774B1 (pt) 2022-01-11
CO6801749A2 (es) 2013-11-29
JP2014517808A (ja) 2014-07-24
UA118248C2 (uk) 2018-12-26
LT2685986T (lt) 2020-03-10
AU2016244305A1 (en) 2016-11-03
WO2012129084A2 (en) 2012-09-27
CN107080747B (zh) 2021-02-26
SI2685986T1 (sl) 2020-03-31
US9126993B2 (en) 2015-09-08
EP2685986A2 (en) 2014-01-22
CN103917094A (zh) 2014-07-09
RU2018104472A3 (es) 2021-04-30
KR101987736B1 (ko) 2019-06-11
HUE047888T2 (hu) 2020-05-28
IL228514B (en) 2019-09-26
TWI546301B (zh) 2016-08-21
GT201300215A (es) 2015-02-09
MX2019008428A (es) 2019-10-30
TW201300383A (zh) 2013-01-01
RU2018104472A (ru) 2019-02-22
HRP20200226T1 (hr) 2020-05-29
CL2013002688A1 (es) 2014-03-07
MX2013010710A (es) 2013-10-17
JP2017141255A (ja) 2017-08-17
RS59963B1 (sr) 2020-03-31
AU2012231275A1 (en) 2013-10-17
RU2645675C2 (ru) 2018-02-27
ZA201307016B (en) 2014-05-28
CN103917094B (zh) 2016-11-09
AU2016244305B2 (en) 2018-05-24
US20160207933A1 (en) 2016-07-21
JP6117708B2 (ja) 2017-04-19
PL2685986T3 (pl) 2020-07-27
EP2685986A4 (en) 2015-03-04
NI201300083A (es) 2014-02-28
MX368340B (es) 2019-09-30
US20140371460A1 (en) 2014-12-18
US20140255381A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY33930A (es) Inhibidores novedosos de quinasas
CR20140024A (es) Compuestos inhibidores de metaloenzimas
CO7020912A2 (es) Inhibidores de bromodominios
UY34365A (es) Compuestos heterociclicos
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY34550A (es) Bencilpirazoles sustituidos
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY34654A (es) Inhibidores de la beta-secretasa
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34523A (es) Derivados de betulina
CR20130539A (es) Triazolopiridinas
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY34119A (es) Montaje machihembrado de fijación
UY34006A (es) Imidazopiridazinas
BR112014003027A2 (pt) formulação herbicida melhorada
UY34442A (es) 2-tiopirimidinonas.
UY34158A (es) Composicion herbicida

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20211015